Visualising neuroinflammation in chronic fatigue syndrome patients

Visualising neuroinflammation in chronic fatigue syndrome patients - Neuroinflammation in CFS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43880

Enrollment

Registered

2016-09-13

Start date

2016-05-31

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vermoeidheidssyndroom chronic fatigue syndrome

Interventions

Chronic Fatigue Syndrome

Neuroinflammation

Positron Emission Tomography

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Control subjects > Female, between 18 and 60 years old; > Neighbourhood control, i.e. live in the same neighbourhood as the CSF patient;CFS patients > CDC-diagnosed CFS-patients; > Female, between 18 and 55 years old; > Score of *40on the subscale fatigue severity of the CIS (Checklist Individual Strength); > Marked functional impairment assessed with the Sickness Impact Profile (SIP-8) and operationalised as a total score of *700.;Patients with Q-fever induced CFS > Diagnosis according to the Dutch guideline on QFS [RIVM, Q-koortsvermoeidheidssyndroom] ; > Female, between 18 and 60 years old ; > Score of *40 on the subscale fatigue severity of the CIS (Checklist Individual Strength); > Marked functional impairment assessed with the Sickness Impact Profile (SIP-8) and operationalised as a total score of *700.

Exclusion criteria

Exclusion criteria: All subjects > Women who are pregnant; > Women who intend to get pregnant during the study; > Use or having used psychotropic medication in the past six months; > Alcohol or substance abuse in the past 3 months; > Use or have used doxycycline in the past six months; > Evident somatic/psychiatric co-morbidity; > Presence of materials in the body that can be magnetized and cannot be removed; > Participation in a scientific research study during the past year involving radiation.;CFS patients and control subjects > History of Q-fever; > Vaccinated for Q-fever

Design outcomes

Primary

Measure	Time frame
The main study parameter is the [11C]PK11195 binding potential in the brain.	—

Secondary

Measure	Time frame
Secondary study parameters are MRI measurements, fatigue severity using the CIS fatigue questionnaire and peripheral cytokine concentrations.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)